ENTA – enanta pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
11/19
03:03 pm
enta
Low
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
11/17
04:45 pm
enta
Low
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
11/17
04:12 pm
enta
Medium
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
11/17
04:01 pm
enta
Low
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
11/14
08:09 am
enta
Low
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
8/11/2025
04:02 pm
enta
1.5%
BEAT
2/10/2025
04:01 pm
enta
14.1%
BEAT
2/10/2025
04:01 pm
enta
14.1%
BEAT
2/10/2025
04:01 pm
enta
14.1%
BEAT
11/14
08:09 am
Initiates
Overweight
JPMorgan Chase & Co.
Low
2.8%
11/14
07:26 am
Initiates
Overweight
JP Morgan
Medium
3.1%
11/14
04:53 am
Initiates
OVERWEIGHT
JPMORGAN
Low
2.9%
10/1
12:25 pm
Upgrades
Hold
Buy
Jefferies
Low
-1.7%
10/1
12:25 pm
Upgrades
Hold
Buy
Jefferies
Low
-1.7%
12/3
05:09 pm
enta
Low
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Capps Kathleen S.
12/3
05:05 pm
enta
Low
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Trout Harry R. III
12/3
05:02 pm
enta
Low
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Luu Brendan
12/3
04:38 pm
enta
Low
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Kieffer Tara Lynn
12/3
04:36 pm
enta
Low
Form 4 ENANTA PHARMACEUTICALS For: Dec 01 Filed by: Or Yat Sun
Show more
Top News Gainers
3/17 Baird likes Enanta's potential in COVID-19, upgrades to Outperform [Seeking Alpha] 11.2%
3/13 Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19 9.2%
2/28 Form 4 ENANTA PHARMACEUTICALS For: Feb 26 Filed by: Russell Lesley 4.1%
5/7 Q2/2019 3/31/2019 EPS 0.200 ZacksConsensus -0.090 ActVsEst 0.290 - Beat 3.8%
2/18 Form 4 ENANTA PHARMACEUTICALS For: Feb 12 Filed by: Luly Jay R. 3.4%
2/3 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.3%
8/12 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 3.3%
11/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 3.2%
9/10 New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019 3.2%
6/26 Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha] 3.1%
Top News Decliners
3/14 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -24.0%
6/14 REFILE-Enanta's lung infection therapy succeeds in mid-stage trial [Reuters] -15.3%
9/25 Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH -15.1%
4/30 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.8%
3/26 Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic -5.4%
2/10 Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 -5.2%
11/21 Q4/2019 9/30/2019 EPS 0.440 ZacksConsensus 0.560 ActVsEst (0.120) - Miss -4.4%
5/10 Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 -4.3%
6/22 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.2%
1/24 Enanta Pharmaceuticals Inc (NASDAQ: ENTA) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -3.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3